Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

[Próba urządzenia niezatwierdzonego lub dopuszczonego przez amerykańską FDA]

16 listopada 2026 zaktualizowane przez: BrainQ Technologies Ltd.

This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment.

The Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery.

The Q Therapeutic System (BQ 3.0) is indicated for adjunctive use in a clinical facility or home setting, in addition to standard-of-care therapies.

  • In Stage 1 (starting 4-21 days after the index stroke event to day 90 post stroke), participants will be randomly assigned (1:1) to receive either active or the sham treatments, up to 5 times a week, and at least to a total of 45 treatments.
  • In Stage 2 (day 90 to day 180 post stroke), participants in both the active and the control group will be allowed to continue to receive active treatments, up to 5 times per week.
  • In stage 3 (day 180 to day 270 post stroke), participants will not receive any treatments and would be followed up until the final visit at day 270.

Each session will last approximately 60 minutes, with stimulation activated for up to 40 minutes, in conjunction with a home-based exercise program. Treatments may be administered in the hospital, in the clinic or in a home setting.

The study will enroll 100-122 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using the BQ 3.0 system.

Przegląd badań

Szczegółowy opis

The study intervention will be initiated 4-21 days after the index stroke event and will consist of 5 treatments per week until the primary endpoint follow-up visit, at day 90 (±15) after the onset of the index stroke. A minimum of 45 treatment sessions should be completed during this stage, with a potential of a maximum of 72 treatment sessions, depending on the start date of the first treatment and the timing of the 90-day follow-up visit. Though, participants and sites will be guided to conduct the 90 days follow-up visit as soon as possible after the 45th treatment session and within up to 7 days from the 45th treatment and after the window opening.

Each treatment session will last approximately 60 minutes and include 40 minutes of active or sham stimulation. Subjects in both groups will be asked to perform a home-based exercise program for the upper and the lower limb, concurrent with the study intervention.

Screening phase:

Prospective subjects, who are 3 to 21 days post-stroke, may be offered informed consent to participate in the study at either:

a participating inpatient or outpatient center, non-participating inpatient or outpatient center, in accordance with both the participating and the non-participating centers' policy, or home Consented subjects, who are 4 to 21 days post-stroke, will be screened for eligibility to participate in the treatment phase of the study.

Eligible subjects will be randomly assigned, at a 1:1 allocation ratio, to either the active or sham study intervention groups.

Stimulation with the Q Therapeutic System (BQ 3.0) does not produce any noticeable sound, light, or tactile sensation which could disclose the treatment arm assignment, making this device ideal for testing in a sham-controlled design. During sham treatment sessions, for purposes of maintaining the blind, the device will function as if it is delivering the therapy (i.e., the device will turn on and all indicators will function), but the frequency and intensity parameters, which are not visible to the subject or site study members (or any blinded personnel), will be set to zero so that no stimulation is delivered.

Stage 1 (day 4 to day 90 (±15) post-stroke) - double-blind sham-controlled:

Efforts should be made to initiate the 1st treatment as early as possible within the window of recruitment, and target to complete a first treatment within 6 days from admission to a participating IRF (where applicable). The study intervention will be initiated 4-21 days after the index stroke event and will consist of 5 treatments per week until the primary endpoint follow-up visit, at day 90 (±15) after the onset of the index stroke. Each treatment session will last approximately 60 minutes and include 40 minutes of active or sham stimulation. Subjects in both groups will be asked to perform a home- based exercise program for the upper and the lower limb, concurrent with the study intervention. The program will be standardized, pre-defined, home-based, and aligned with standard-of-care1.

The participant and their caregiver will be trained on the use of the device and exercise program. Treatment sessions will be completed by the subject with the assistance of a trained caregiver, as needed. Periodic supervision will be provided by the study team (combined audio and video remote conferencing or audio only, if video is not available). A sponsor's representative may provide in-person or remote technical support to the participant and their caregiver, as well as device training, as needed.

Subjects will undergo a detailed interim outcome assessment on the 45th (±4) day after the onset of the index stroke, and a detailed primary endpoint outcome assessment on the 90th (±15) day after the onset of the index stroke. In addition, a focused, long-term outcome assessment on the 180th (±15) day after the onset of the index stroke will be performed.

Stage 2 (day 90 (±15) to day 180 (±15) post-stroke) - open-label:

Subjects in both the active and the sham groups (active /sham), who were adherent to the treatment in Stage 1 (defined as at least 35 completed treatment sessions in Stage 1) will be allowed to continue to receive active EMFstimulation treatments (i.e., with the electromagnetic therapy turned on).

Up to 5 active treatments per week will be completed, starting following the primary endpoint assessment follow-up visit at 90 (±15) days after the onset of the index stroke and continuing until the follow-up visit at 180 (±15) days after the onset of the index. Technically, a maximum of 86 treatment sessions can be completed during stage 2, depending on the timing of the 90-day and 180-day follow-up visits.

The blind, with respect to the group allocation in Stage 1, would be maintained for all parties (participants, investigators, assessors and Sponsor) until the trial completion and database lock.

Each session will last approximately 60 minutes and include 40 minutes of active stimulation. Subjects will be asked to perform a home-based exercise program, concurrent with the study intervention.

Treatment sessions will be completed by the subject with the assistance of a trained caregiver, as needed. Periodic supervision will be provided by the study team (combined audio and video remote conferencing or audio only, if video is not available). A sponsor's representative willmay provide in-person or remote technical support to the participant and their caregiver, as well as device training, as needed.

All subjects, including those who decided not to continue to receive treatments in Stage 2, will undergo a detailed follow-up assessment on the 180th (±15) day after the onset of the index stroke.

Stage 3 (day 180 (±15) to day 270 (±15) post-stroke):

At this Stage, no treatments sessions will take place. All subjects, including those who decided not to continue to receive treatments in Stage 2, will undergo In addition, aa focused, long-term outcome assessment on the 180th 270th (±15) day after the onset of the index stroke will be performed.

Any adverse events and device deficiencies occurring during the period of subject's participation in the trial will be recorded.

Participation in the study will not replace any of the usual care patient should receive.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

62

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • California
      • Downey, California, Stany Zjednoczone, 90242
        • Rancho Research Institute
    • District of Columbia
      • Washington D.C., District of Columbia, Stany Zjednoczone, 20010
        • MedStar National Rehabililtaion Hospital,
    • Florida
      • Jacksonville, Florida, Stany Zjednoczone, 32216
        • Brooks Rehabilitation Hospital
    • Georgia
      • Altanta, Georgia, Stany Zjednoczone, 30322
        • Emory University School of Medicine
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60611
        • Shirley Ryan AbilityLab
    • Kansas
      • Kansas City, Kansas, Stany Zjednoczone, 66160
        • KUMC- KU Medical Center
    • New Jersey
      • Edison, New Jersey, Stany Zjednoczone, 08818
        • Hackensack Meridian JFK Johnson Rehabilitation Institute
      • West Orange, New Jersey, Stany Zjednoczone, 07052
        • Kessler Foundation for Rehabilitation
    • New York
      • Brooklyn, New York, Stany Zjednoczone, 11215
        • New York-Presbyterian Brooklyn Methodist Hospital Inpatient Rehabilitation Unit
      • White Plains, New York, Stany Zjednoczone, 10605
        • Burke Rehabilitation Hospital
    • North Carolina
      • Charlotte, North Carolina, Stany Zjednoczone, 28203
        • Atrium Health Carolinas Rehabilitation
    • Pennsylvania
      • Elkins Park, Pennsylvania, Stany Zjednoczone, 19027
        • Moss Rehabilitation Research Institute
    • Texas
      • Houston, Texas, Stany Zjednoczone, 77030
        • UTHealth Houston
    • Wisconsin
      • Milwaukee, Wisconsin, Stany Zjednoczone, 53226
        • Froedtert & Medical College of Wisconsin

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

22 lata do 80 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. mRS score of 3 or 4.
  2. FMA-UE score between 10-45 (inclusive) of impaired limb.
  3. SAFE score >0.
  4. Age 22 to 80 years of age (inclusive).
  5. Diagnosed with an ischemic stroke, confirmed by CT4 or MRI5 imaging.
  6. First ever ischemic stroke, or a recurring ischemic stroke6 occurring at least 3 months after the previous stroke (any stroke), without residual neurological impairment or disability before current stroke.
  7. Four to 21 days from stroke onset (or last known well).
  8. Pre-stroke mRS of 0.
  9. Able to sit with the investigational device for 40 consecutive minutes, in the opinion of the investigator or designee.
  10. Can follow a 3-step command, such as "take the paper, fold it in half, and return it to me".
  11. Willingness to participate in an exercise activity during study intervention sessions.
  12. Availability of a relative or other caregiver able to assist in operating an application installed on a mobile device, including a video call, and assist the participant with the exercising program.
  13. If female, not pregnant (as confirmed by a urine or a blood test, or as determined by an official medical document) or breastfeeding and with no ability to become pregnant or on an acceptable method of contraception during the study
  14. Informed consent signed by subject.

Exclusion Criteria:

  1. Hemineglect impairment (NIHSS item 11, score >0).
  2. Implanted active electronic or passive MR-incompatible devices.
  3. Pre-existing major neurological condition (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or pre-existing physical limitation that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  4. Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or any epileptic seizure in the last 5 years
  5. Significant visual disturbances, pre-existing or resulting from the index stroke, that cannot be corrected and that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  6. Unstable serious illness/condition (eg, active cancer, severe heart failure, active major psychiatric condition) or life expectancy of less than 12 months.
  7. A known severe allergic reaction to acrylic-based adhesives.
  8. Alcohol abuse and/or illicit drug abuse in the past 6 months, which is likely to influence ability to fully participate in the trial.
  9. Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.
  10. Employee of the Sponsor.
  11. Prisoner.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie podtrzymujące
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Pozorny komparator: BQ 3.0 Sham Stimulation Group

Q Therapeutic System (BQ 3.0) sham stimulation group:

Device used: Q Therapeutic System (BQ 3.0)

In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 3.0 (frequency and intensity parameters will be set to zero so that no stimulation is delivered) including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.

Inne nazwy:
  • Grupa pozorowanej stymulacji BQ 3.0

The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

Inne nazwy:
  • BQ 3.0 Interwencje grupowe aktywnej stymulacji
Aktywny komparator: BQ 3.0 Active Stimulation Group

Q Therapeutic System (BQ 3.0) active stimulation group:

Device used: Q Therapeutic System (BQ 3.0)

In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with the BQ 3.0 (frequency and intensity parameters will be set to 1-100 Hz.; 0.1-1.0 G), including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.

Inne nazwy:
  • Grupa pozorowanej stymulacji BQ 3.0

The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

Inne nazwy:
  • BQ 3.0 Interwencje grupowe aktywnej stymulacji

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change from Baseline in Modified Rankin Scale
Ramy czasowe: 4 to 21 days following an ischemic stroke to 90-day post-stroke

Proportion of subjects achieving an excellent outcome defined as a Modified Rankin Scale (mRS) score of 0-1 at the 90-day post-stroke assessment, reflecting freedom from disability.

4 to 21 days following an ischemic stroke to 90-day post-stroke

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Analiza przesunięć porządkowych mRS (trichotomizacja przy 0-1, 2, 3-6) (Kluczowy drugorzędowy punkt końcowy dotyczący skuteczności)
Ramy czasowe: punkt wyjściowy do oceny 90 dni po udarze
punkt wyjściowy do oceny 90 dni po udarze
Analiza przesunięć porządkowych mRS (4 poziomy w punktach 0, 1, 2, 3-6) z oceny 90 dni po udarze do oceny 180 dni po udarze, w grupie osób aktywnych, które kontynuowały leczenie w Etap 2
Ramy czasowe: od oceny 90-dniowej po udarze do oceny 180-dniowej po udarze
od oceny 90-dniowej po udarze do oceny 180-dniowej po udarze
Change from Baseline in Modified Rankin Scale (Key Secondary Effectiveness Endpoint)
Ramy czasowe: baseline (4-21 days post-stroke) to 90 days post-stroke

To show that the BQ therapy is effective in reducing disability levels

baseline (4-21 days post-stroke) to 90 days post-stroke
Proportion of subjects achieving functional independence (mRS score of 0-2) (Key Secondary Effectiveness Endpoint)
Ramy czasowe: at the 90-day post-stroke assessment

To show that the BQ therapy is effective in achieving functional independence.

at the 90-day post-stroke assessment
Stroke Impact Scale Hand Domain (Lead Secondary Endpoint)
Ramy czasowe: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

Patient reported hand function - To show that the BQ therapy is effective in improving upper limb impairment and function

baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke
Stroke Impact Scale 16
Ramy czasowe: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

Patient-reported physical function - To show that the BQ therapy is effective in improving physical function

baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke
10-meter Walk Test
Ramy czasowe: change from baseline to 90 days post-stroke

The Functional Ambulation Categories (FAC) will be collected concurrent to the 10MWT to assess the level of independent ambulation.

change from baseline to 90 days post-stroke
Box and Block Test
Ramy czasowe: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

Arm motor function - To show that the BQ therapy is effective in improving Arm motor function

baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke
Evaluation of 5-level EQ-5D
Ramy czasowe: At 90-days post-stroke

Health-related quality of life - To show that the BQ therapy is effective in achieving health-related quality of life (HRQoL)

At 90-days post-stroke
Fugl-Meyer Assessment for Upper Extremity (FMA-UE)
Ramy czasowe: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

upper limb impairment - To show that the BQ therapy is effective in achieving reducing upper limb impairment, and improving upper limb function

baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke
Nine-Hole Peg Test
Ramy czasowe: change from baseline to 90-days post-stroke

finger dexterity - To show that the BQ therapy is effective in achieving reducing upper limb impairment, and improving upper limb function

change from baseline to 90-days post-stroke
The proportion of subjects within those in the active group who continued to receive treatments in Stage 2, achieving an excellent outcome (defined as a mRS of 0-1) at the 180-day post-stroke assessment.
Ramy czasowe: at the 180-day post-stroke assessment

To show, within those in the active group who continued to receive treatments in Stage 2, that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 4 to 21 days following an ischemic stroke.

at the 180-day post-stroke assessment
The proportion of patients within those in the active group who continued to receive treatments in Stage 2, who achieved an excellent outcome defined as a mRS score of 0-1 at the 90-day post-stroke assessment and had an mRS >1 at 180-day post-stroke
Ramy czasowe: at 180 days post-stroke

To show, within those in the active group who continued to receive treatments in Stage 2, that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 4 to 21 days following an ischemic stroke

at 180 days post-stroke
The proportion of patients within those in the active group who continued to receive treatments in Stage 2, who achieved an excellent outcome defined as mRS score of 0-1 at the 180-day post-stroke assessment and had an mRS >1 at 270 days post-stroke.
Ramy czasowe: at 270 days post-stroke

To show, within those in the active group who continued to receive treatments in Stage 2, that the effect attained in obtaining freedom from disability, as well as reducing global disability, is maintained at 6- and 9- months post-stroke in disabled patients with upper limb motor impairment when initiated 4 to 21 days following an ischemic stroke.

at 270 days post-stroke
The proportion of patients who improved by at least 1 level on the mRS from the 90-day post-stroke assessment to 180-day post-stroke assessment, within those in the active group who continued to receive treatments in Stage 2.
Ramy czasowe: from the 90-day post-stroke assessment to 180-day post-stroke assessment

To show, within those in the active group who continued to receive treatments in Stage 2, that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 4 to 21 days following an ischemic stroke

from the 90-day post-stroke assessment to 180-day post-stroke assessment
The proportion of subjects within those in the sham group who continued to receive treatments in Stage 2, achieving an excellent outcome (defined as a mRS of 0-1) at the 180-day post-stroke assessment, and had an mRS >1 at 90 days post-stroke.
Ramy czasowe: from the 90-day assessment to the 180-day assessment

To show, within those in the sham group who continued to receive treatments in Stage 2 that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 90 days following an ischemic stroke

from the 90-day assessment to the 180-day assessment

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Serious procedure or device related adverse events & device deficiencies
Ramy czasowe: Through study completion, an average of 90 ± 15 days post-stroke

To characterize the safety profile of the BQ therapy and to show that the BQ 3.0 performs reliably.

Through study completion, an average of 90 ± 15 days post-stroke
Change in Montreal Cognitive Assessment (global cognitive function)
Ramy czasowe: at 90-day post-stroke

To show that the BQ therapy is effective in reducing cognitive impairment, at 3 months post-stroke, when initiated 4 to 21 days following an ischemic stroke.

at 90-day post-stroke
Change in Patient Health Questionnaire-8 (depression)
Ramy czasowe: at 90-day post stroke

To show that the BQ therapy is effective in reducing depression, at 3 months post-stroke, when initiated 4 to 21 days following an ischemic stroke.

at 90-day post stroke
Academic Medical Center Linear Disability Scale (granular level of disability)
Ramy czasowe: At 90 days post stroke

To show that the BQ therapy is effective in reducing fine-grained level of disability at 3 months post-stroke

At 90 days post stroke
Proportion of subjects achieving functional independence (modified Rankin Scale score of 0-1)
Ramy czasowe: at 45 days post-stroke

To show that the BQ therapy is effective in increasing functional independence at 1.5 months post-stroke

at 45 days post-stroke
Zarit Burden Interview
Ramy czasowe: at midterm, 90 days post-stroke, 180 days post-stroke, and 270 days post-stroke.

To formally evaluate the cost-effectiveness of the BQ therapy via caregiver burden.

at midterm, 90 days post-stroke, 180 days post-stroke, and 270 days post-stroke.
Formal cost-effectiveness analysis over a lifetime horizon from the perspective of the United States healthcare system.
Ramy czasowe: will be assessed at MidTerm (45 Day ± 4 days post- stroke) , Day-90 and D-180 post stroke

To formally evaluate the cost-effectiveness of the BQ therapy over a lifetime horizon from the perspective of the United States healthcare system

will be assessed at MidTerm (45 Day ± 4 days post- stroke) , Day-90 and D-180 post stroke
Relationship between adherence to treatment as measured by the Qompass and the clinical outcomes.
Ramy czasowe: Will be assessed upon data base lock

To explore the relationship between adherence to treatment as measured by the Qompass and clinical outcomes.

Will be assessed upon data base lock
The proportion of patients within those in the sham group who continued to receive treatments in Stage 2 who improved from the 90-day assessment to 180-day and the improvement was maintained at 270 days post-stroke
Ramy czasowe: At 180 days post stroke and 270 days post-stroke

To show, within those in the sham group who continued to receive treatments in Stage 2 that the BQ therapy is effective in improving functional independence at 6 months post-stroke, when initiated 90 days following an ischemic stroke.

At 180 days post stroke and 270 days post-stroke

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Krzesło do nauki: Jeffrey L. Saver, MD, Coordinating PI
  • Główny śledczy: Joel Stein, MD, Coordinating PI

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

20 sierpnia 2024

Zakończenie podstawowe (Rzeczywisty)

26 grudnia 2025

Ukończenie studiów (Rzeczywisty)

7 kwietnia 2026

Daty rejestracji na studia

Pierwszy przesłany

16 kwietnia 2024

Pierwszy przesłany, który spełnia kryteria kontroli jakości

24 kwietnia 2024

Pierwszy wysłany (Rzeczywisty)

26 kwietnia 2024

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

19 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

16 listopada 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

will be shared following site level approval

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Tak

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj